pipette
ENEnglish

Allosteric covalent inhibition of cereblon through cryptic cysteine targeting

Z. Rizvi, B. E. Nordin, K. T. Symons, K. A. Baltgalvis, D. S. Weinstein, M. P. Patricelli, G. Simon, G. C. Lander

PreprintUso en el mundo real

En palabras de los autores

Thalidomide-derived cereblon (CRBN) modulators are among the most clinically impactful targeted protein degradation therapeutics, redirecting the CRL4-CRBN E3 ubiquitin ligase to degrade disease-driving neosubstrates. All current CRBN-targeting IMiDs and CELMoDs engage a single orthosteric pocket, leaving CRBN's conformational landscape largely unexploited pharmacologically. Using cysteine-directed chemoproteomic screening, we identified covalent ligands that engage Cys287, a cryptic allosteric pocket distal to the orthosteric site. Our lead compound, VVD-105917, acts as a pan-inhibitor of IMiD/CELMoD-driven neosubstrate degradation. Cryo-EM structures reveal that covalent Cys287 engagement traps CRBN in its open, inactive conformation, resolving a previously unobserved N-terminal segment and sensor loop. Sequential incubation experiments show the conformational outcome depends on ligand addition order, demonstrating that even potent CELMoD-driven closure can be overridden by allosteric engagement. A recently reported ligand at this same pocket produces the opposite effect, promoting rather than blocking closure, indicating the Cys287 site is mechanistically sign-switchable. These findings establish covalent chemoproteomics as a strategy for discovering and controlling E3 ligase conformational switches.

Resultado principalEl resumen no menciona limitaciones.

Apareció: viernes, 16 de octubre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.10.10.758245